特発性男子不妊症におけるhCG/hMG剤の併用について

Abstract

1)いわゆる特発性男子不妊症に対して, hCG, hMGの併用療法を施行し, 性ホルモン, 睾丸容積と精子数におよぼす影響について検討した.2)投与方法および投与量については対象を無作為に2群に分類, Group 1に対してはhCG 1, 000国際単位とhMG 75国際単位を週1回筋肉内投与した.Group 2に対してはhCG 1, 000国際単位とhMG 150国際単位を週1回筋肉内投与した.3)両群間には, 年齢, 加療前の睾丸容積, 血清LH, FSH, testosterone, prolactinについて有意差を認めていない.4)治療開始12週後, 精子数濃度が治療前値に比べ1, 000万/ml以上の改善が得られたものはGroup 1で26%, Group 2で24%であり, 治療期間中に妊娠成立が得られたものはGroup 1の4例(15%)であった.5)血清LH, testosterone, prolactin基礎値には治療期間中有意な変動はみられなかった.6)睾丸容積は治療前後で有意な変化は認められなかった

Changes in sex hormone levels, testicular volume and sperm count during hCG/hMG therapy were studied in 44 cases of idiopathic male infertility. These patients were divided into two groups and treated for 12 weeks. In group I, which consisted of 5 cases of azoospermia, 10 cases of severe oligozoospermia (less than 10 X 10(6)/ml) and 12 cases of mild oligozoospermia (10-50 X 10(6)/ml), 1, 000 IU of hCG and 75 IU of hMG were both administered once a week. In group II, which consisted of 3 cases of azoospermia, 7 cases of severe oligozoospermia and 7 cases of mild oligozoospermia, 1, 000 IU of hCG and 150 IU of hMG were both administered once a week. After 12 weeks, increase in sperm count was observed in 7 cases (26%) in group I and 4 cases (24%) in group II. Pregnancy was ensued in 4 cases in group I. There was no significant changes in testicular volume or sex hormone levels during hCG/hMG therapy.